SCHEMBL5310780

SCHEMBL5310780

N#CC1CC1c1ccc(Br)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 9/20 0.52
MAOB P27338 5/20 0.52
KCNH2 Q12809 2/20 0.52
RCOR1 Q9UKL0 2/20 0.52
KDM1B Q8NB78 1/20 0.52
HTR2C P28335 2/20 0.46
HTR2B P41595 2/20 0.46
KDM4E B2RXH2 1/20 0.39
GAA P10253 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MAOA P21397 2/20 0.38
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34
CYP2A6 P11509 1/20 0.33
MAPT P10636 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2324654 0.79 KDM1A (0.52) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL9544430 0.79 HTR2A (0.44) KDM1AHTR2CHTR2BKDM4ECYP2C9
SCHEMBL18704254 0.79 HTR2A (0.44) KDM1AMAOBHTR2CHTR2BGAA
SCHEMBL5450245 0.78 MAOB (0.48) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL29134399 0.77 KDM1A (0.58) KDM1ARCOR1HTR2CHTR2BL3MBTL1
SCHEMBL29134397 0.77 KDM1A (0.58) KDM1ARCOR1HTR2CHTR2BL3MBTL1
SCHEMBL30016116 0.77 KDM1A (0.58) KDM1ARCOR1HTR2CHTR2BL3MBTL1
SCHEMBL27200339 0.75 KDM1A (0.47) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL9543138 0.75 KDM1A (0.56) KDM1AMAOBHTR2CKDM4EGAA
SCHEMBL21236196 0.74 KDM1A (0.60) KDM1AKCNH2RCOR1KDM1BHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1517895-B1 8-(BIARYL) QUINOLINE PDE4 INHIBITORS MERCK FROSST CANADA LTD (CA) 2007-03-14 EP disclosed
US-7153968-B2 8-(biaryl)quinoline PDE4 inhibitors MERCK FROSST CANADA, LTD. (CA) 2006-12-26 US disclosed
US-20050234238-A1 8-(Biaryl)quinoline pde4 inhibitors MERCK FROSST CANADA LTD. (CA) 2005-10-20 US disclosed
EP-1517895-A1 8-(BIARYL) QUINOLINE PDE4 INHIBITORS MERCK FROSST CANADA INC. (CA) 2005-03-30 EP disclosed
WO-2004000814-A1 8-(BIARYL) QUINOLINE PDE4 INHIBITORS MERCK FROSST CANADA & CO. (CA) 2003-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234238-A1 8-(Biaryl)quinoline pde4 inhibitors IL4, PDE4A, PDE4C KDM1A 3757/4885MAOB 1355/4885KCNH2 2968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.